Does Intravenous Iron Therapy Decrease Serum Phosphorous Levels?

NCT02420119 | Completed Results

• 1 other identifier: EMC 59-14
• Study Type: observational
• Target: 53
• Locations: 1 country
• Sites: 1

Brief Summary

Intravenous iron therapy is common and effective, with few side effects. Two formulations are used, venofer or iron sucrose and ferrlecit, or ferric gluconate. The association between intravenous iron use and decrease in serum phosphorus and vitamin D levels, with increased fractional excretion of phosphorus, has been observed with older iron preparations, such as saccharated ferric oxide. However, hypophosphatemia and osteomalacia have been reported with iron carboxymaltose, a newer iron formulation. There is no information in the literature about phosphorus and vitamin D levels after treatment with venofer or ferrlecit. We intend to check phosphorus and vitamin D serum levels in our patients prior to and after treatment with these iron formulations.

Conditions

Chronic Renal Failure

Keywords

Iron Therapy; serum phosphates; vitamin D

Outcome Measures

Primary Outcomes (1)

• Decrease in Serum Levels of Phosphorus in Patients After Treatment With Intravenous Iron.

  serum phosphorus levels were measure at baseline, and after intravenous iron administration

  3 month

Interventions

non interventional OTHER

Eligibility Criteria

• Age: 18 Years+
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)
• Sampling Method: Non-Probability Sample

Study Population

in a period of one year we will try to recruit approximately 100 men and women over the age of 18, who have iron deficiency anemia and have been prescribed intravenous iron treatment at the ambulatory treatment unit.

You may qualify if:

• Age 18 and over
• Have an indication for intravenous iron treatment
• Estimated Creatinine clearance at least 30ml/min (patients with lower Estimated Creatinine clearance may not be able to excrete phosphorus)
• Have signed informed consent.

You may not qualify if:

• Pregnancy
• Estimated creatinine clearance below 30 ml/min.

Sponsors & Collaborators

• Frieda Wolf: lead

Study Sites (1)

Haemek medical center

Afula, Israel

Location

MeSH Terms

Conditions

Kidney Failure, Chronic

Condition Hierarchy (Ancestors)

Renal Insufficiency, Chronic; Renal Insufficiency; Kidney Diseases; Urologic Diseases; Female Urogenital Diseases; Female Urogenital Diseases and Pregnancy Complications; Urogenital Diseases; Male Urogenital Diseases; Chronic Disease; Disease Attributes; Pathologic Processes; Pathological Conditions, Signs and Symptoms

Results Point of Contact

• Title: Dr.Frieda Wolf
• Organization: HaEmek Medical Center

friedawolf@hotmail.com

97246495476

Publication Agreements

• PI is Sponsor Employee: No
• Restrictive Agreement: No

Study Design

• Study Type: observational
• Observational Model: COHORT
• Time Perspective: PROSPECTIVE
• Sponsor Type: OTHER
• Responsible Party: SPONSOR INVESTIGATOR
• PI Title: Dr frieda wolf

Study Record Dates

• First Submitted: April 14, 2015
• First Posted: April 17, 2015
• Study Start: January 1, 2015
• Primary Completion: January 1, 2016
• Study Completion: January 1, 2016
• Last Updated: August 9, 2022
• Results First Posted: August 9, 2022

Record last verified: 2022-08

Data Sharing

• IPD Sharing: Will not share

Locations

IL (1)